A pharmacological analysis of stimulant-induced increases in smoking

Psychopharmacology

Volumn 193, Issue 3, 2007, Pages 305-313

  Vansickel, Andrea R ^a,b   Stoops, William W ^a   Glaser, Paul E A ^a   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

ADHD; Atomoxetine; Humans; Methylphenidate; Smoking; Subjective effects

Indexed keywords

ATOMOXETINE; CARBON MONOXIDE; CENTRAL STIMULANT AGENT; DOPAMINE; METHYLPHENIDATE; NICOTINE; PLACEBO;

ADULT; ARTICLE; CALCULATION; CARBON MONOXIDE BLOOD LEVEL; CIGARETTE SMOKING; COMPREHENSION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG USE; EXPERIMENT; FEMALE; FOOD INTAKE; HUMAN; MALE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RESEARCH;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; EATING; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; QUESTIONNAIRES; SMOKING;

EID: 34447309355     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0786-z     Document Type: Article

References (53)

1. Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001) Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154:76-84
2. Berridge KC (1996) Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1-25
3. Biederman J, Wilens T, Mick E, Spencer T, Faraone S (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104(2):20-25
4. Bray GA (1993) Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 7(2):707-713
5. Budney AJ, Higgins ST, Hughes JR, Bickel WK (1993) Nicotine and caffeine use in cocaine-dependent individuals. J Subst Abuse 5(2):117-130
6. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
7. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH (2005) Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry 66(10):1234-1238
8. Center for Disease Control (CDC) (2003) Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999. MMWR Weekly 51(14):300-303
9. Chait LD, Griffiths RR (1983) Effects of caffeine on cigarette smoking and subjective response. Clin Pharmacol Ther 34:612-622
10. Christman AK, Fermo JD, Markowitz JS (2004) Atomoxetine, a novel treatment for Attention-Deficit-Hyperactivity Disorder. Pharmacotherapy 24(8):1020-1036
11. Cousins MS, Stamat HM, de Wit H (2001) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243-253
12. Feinberg SS (2004) Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 65(11):1520-1524
13. Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB (2006) Atomoxetine for weight reduction in obese women: a preliminary randomized controlled trial. Int J Obes 30:1138-1142
14. Gehlert DR, Schober DA, Hemrick-Luecke SK, Krushinski J, Howbert JJ, Robertson DW, Fuller RW, Wong DT (1995) Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int 26:47-52
15. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL (2000) Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38:432-437
16. Gottlieb S (2001) Methylphenidate works by increasing dopamine levels. BMJ 322:259
17. Hamada M, Higashi H, Nairn AC, Greengard P, Nishi A (2004) Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J Neurochem 90:1094-1103
18. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002) Comparison of the subjective, physiological and psychomotor effects of methylphenidate and atomoxetine in light drug users. Drug Alcohol Depend 67:149-156
19. Henningfield JE, Griffiths RR (1981) Cigarette smoking and subjective response: effects of d-amphetamine. Clin Pharmacol Ther 30:497-505
20. Henningfield JE, Lukas SE, Bigelow GE (1986) Human studies of drugs as reinforcers. In: Goldberg, Stolerman (eds) Behavioral analysis of drug dependence (Chapter 3). Academic, Orlando, FL
21. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML (2005) Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55(5):281-299
22. Huston-Lyons D, Sarkar M, Kornetsky C (1993) Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide. Pharmacol Biochem Behav 46:453-457
23. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6(4):367-374
24. Lage M, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 12(4):575-581
25. Lambert NM (2002) Stimulant treatment as a risk factor for nicotine use and substance abuse. In: Jensen PS, Cooper JR (eds) Attention deficit hyperactivity disorder: state of the science-best practices (Chapter 18). Civic Research Institute, Kingston, NJ
26. Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31(6):533-544
27. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH (2000) Smoking and mental illness: a population-based prevalence study. JAMA 284:2606-2610
28. Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, Lerman C (2004) Influence of methylphenidate on eating in obese men. Obes Res 12:224-232
29. Lile JA, Stoops WW, Durell TM, Glaser PEA, Rush CR (2006) Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 14(2):136-147
30. Loney J, Kramer J, Salisbury H (2002) Medicated versus unmedicated ADHD children-adult involvement with legal and illegal drugs. In: Jensen PS, Cooper JR (eds) Attention defecit hyperactivity disorder: state of the science-best practices (Chapter 17). Civic Research Institute, Kingston, NJ
31. Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Gage HD, Morton TE (1997) Use of positron emission tomography to study the dynamics of psychostimulant release. Pharmacol Biochem Behav 57(3):477-486
32. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
33. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
34. Mignot E, Nishino S (2005) Emerging therapies in narcolepsy-cataplexy. Sleep 28(6):754-763
35. Nisoli E, Carruba MO (2000) An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1(2):127-139
36. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW (1992) Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 261:885-894
37. Reeves G, Schweitzer J (2004) Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 5:1313-1320
38. Rush CR, Essman WD, Simpson CA, Baker RW (2001) Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing volunteers. J Clin Psychopharmacol 21:273-286
39. Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PEA (2005) Methylphenidate increases cigarette smoking. Psychopharmacology 181:781-789
40. Schuster CR, Lucchesi BR, Emley GS (1979) The effects of d-amphetamine, meprobamate, and lobeline on the cigarette smoking behavior of normal human subjects. NIDA Res Monogr 23:91-99
41. Schwartz JR (2004) Pharmacological management of daytime sleepiness. J Clin Psychiatry 65(S16):46-49
42. Sigmon SC, Tidey JW, Badger GJ, Higgins ST (2003) Acute effects of d-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology 167:393-402
43. Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205-222
44. Spencer T, Biederman J, Wilens T (2004) Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:361-372
45. Stoops WW, Lile JA, Fillmore MT, Glaser PEA, Rush CR (2005a) Reinforcing effects of methylphenidate: Influence of dose and environmental demands following drug administration. Psychopharmacology 177:349-355
46. Stoops WW, Lile JA, Glaser PEA, Rush CR (2005b) Discriminative-stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol 13:56-64
47. Substance Abuse and Mental Health Services Administration (2006) Results from the 2005 National Survey on Drug Use and Health: national findings. Office of Applied Studies, NSDUH Series H-30, DHHS Publication no. SMA 06-4194, Rockville, MD
48. Tidey JW, O'Neill SC, Higgins ST (2000) d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl) 153:85-92
49. Volkow ND, Wang GJ, Fowler JS, Ding YS (2005) Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11):1410-1415
50. Wee S, Woolverton WL (2004) Evaluation of the reinforcing effects of atomoxetine in monkeys: a comparison to methylphenidate and desipramine. Drug Alcohol Depend 75(3):271-276
51. Weigle DA (2003) Pharmacological treatment of obesity: past, present, and future. J Clin Endocrinol Metab 88(6):2462-2469
52. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR (2006) Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Peds 149:112-119
53. Wooters TE, Neugebauer NM, Rush CR, Bardo MT (2007) Methylphenidate enhances the abuse-related effects of nicotine in rats: intravenous self-administration, drug-discrimination and locomotor sensitization. Neuropsychopharmacology (under review)